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Abstract
Background: Ischemia reperfusion (I/R) is common in various pathological conditions like diabetic complication, 
rheumatic arthritis, necrotizing vascular occlusive disease and trauma.
Methods: We have evaluated the effect of tacrolimus (1, 2 and 3 mg/kg, p.o. for 10 consecutive days) on femoral 
arterial ischemic reperfusion (I/R) induced neuropathic pain in rats. Behavioral parameters (i.e. hot plate, radiant heat, 
acetone drop, tail heat hyperalgesia, tail flick and tail cold allodynia tests) were assessed at different time intervals (i.e. 0, 
1, 4, 7, 10, 13 and 16th day) and biochemical analysis in serum and tissue samples were also performed along with 
histopathological studies.
Results: Behavioral pain assessment revealed increase in the paw and tail withdrawal threshold in tacrolimus treated 
groups against hyperalgesic and allodynic stimuli as compared to the sham control group. We observed a decrease in 
the serum nitrate and thiobarbituric acid reactive substance (TBARS) levels along with reduction in tissue 
myeloperoxidase (MPO) and total calcium levels, whereas, rise in tissue reduced glutathione levels in tacrolimus treated 
groups. However, significant results were obtained in medium and high dose treated group as compared to sham 
control group. Histopathological study had revealed the increase in the neuronal edema and axonal degeneration in 
the I/R group whereas, tacrolimus ameliorate these effects.
Conclusion: Our results indicate the anti-oxidative, anti-inflammatory and calcium modulatory actions of tacrolimus. 
Therefore, it can be used as a therapeutic agent for the treatment of vascular inflammatory related neuropathic pain.
Introduction
Clinically, neuropathic pain is characterized by sensory
symptoms, impairment of motor function as well as vaso-
motor and sudomotor abnormalities that typically show a
spreading tendency with a generalized distal distribution
[1]. The peripheral mechanism discussed above include
immune cell mediated inflammatory process [2,3], auto-
immune inflammatory process [4], neurogenic inflamma-
tion [3,5] and tissue hypoxia [6]. However, according to
central mechanism develops as a consequence of reorga-
nization of somatosensory, somatomotor and autonomic
systems in the CNS triggered by a peripheral input [7].
Novel neuropathic pain model has been proposed in
complex regional pain syndrome (CRPS) produced by
prolonged hindpaw ischemia and reperfusion in rat [8].
Ischemic-reperfusion event is well documented to induce
potent injury in the targeted organs, which were indi-
cated in the myocardial, renal, liver, lung, stomach and
neuronal cells [9-11]. Ischemic-reperfusion process leads
to change in the microvascular environment which in
turn causes neuronal edema, breakdown of blood-nerve
barrier, nerve fiber degeneration, neuronal excitation,
decreased nerve conduction velocity, membranous lipid
peroxidation, accumulation of free radical, alteration of
enzymatic reaction, ion fluxes etc [12,13].
This alteration in neuronal blood flow and neuronal
function may leads to partial and/or permanent impair-
ment of quality of life in neuropathic patients. Certain
pathological conditions are responsible for the develop-
ment of vasculatic neuropathy such as diabetes mellitus,
vascular occlusive diseases, necrotizing vasculitides,
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peripheral arterial disease, trauma etc [14]. Moreover,
peripheral vascular changes are common progressive fac-
tors for the acute and chronic ischemic neuropathic pain
in patients [15].
The pathophysiology of I/R injury include platelet
aggregation, immune cell activation, free radical genera-
tion and leukocyte-endothelial cell interactions which
lead to the injury of the endothelium and obstruction of
capillaries, thus impairing oxygen supply to the nerve tis-
sue [16]. Tacrolimus (FK506) is a potent immunosuppres-
sive drug that has been widely used for organ
transplantation and atopic dermatitis. Recently, clinical
studies have demonstrated the beneficial effects of this
agent in the treatment of various autoimmune and
inflammatory diseases such as, rheumatoid arthritis and
inflammatory bowel diseases [17]. Tacrolimus has also
been reported to possess ameliorative role in the peptic
ulcer due to its antioxidant and immunosuppressive
action [18]. Therefore, the present study was designed to
investigate the ameliorative effect of FK-506 (tacrolimus)
on femoral ischemia-reperfusion injury induced neuro-
pathic pain in rats.
Materials and methods
Animal
Wistar rats of either sex weighing between 180-250 g
were used. Animals were procured from Punjab Agricul-
ture University, Department of Animal Sciences, Ludhi-
ana. They were kept at standard laboratory diet,
environmental temperature and humidity. A 12 h natural
light and dark cycle was maintained throughout the
experimental protocol. The animals had free access to
standard laboratory chow and water ad libitum. The
experimental protocol was duly approved by Institutional
Animal Ethics Committee (IAEC) and care of the animals
was carried out as per the guidelines of Committee for
the Purpose of Control and Supervision of Experiments
on Animals (CPCSEA), Ministry of Environment and
Forest, Government of India (Reg No:- 874/ac/05/CPC-
SEA).
Chemicals
DTNB (5,5'-dithio bis (2-nitrobenzoic acid), BSA (Bovine
Serum Albumin), (GSH) reduced glutathione were pur-
chased from Sisco Research Laboratories, Mumbai. Thio-
barbituric acid was purchased from Loba Chemie,
Mumbai. All other reagents were obtained from S.D. Fine
Chemicals, Mumbai, India.
Surgical procedure
Rats were anesthetizsed intraperitoneally with ketamine
HCl (50 mg/kg) and xylazine (5 mg/kg). Animals were
then placed in supine position on a heated mat during the
operation and recovery. Right femoral vessels were
exposed through an inguinal incision and were dissected
free from the femoral nerve under operating microscope.
Near the trifurcation of the sciatic nerve (into peroneal,
tibial and sural branches) ischemia was developed for
three hours by occluding the femoral artery with a silk
suture (6-0) using slipknot technique [19] and later on
reperfusion was achieved by the removal of this ligature.
Venous and femoral nerve occlusion was carefully
avoided. To prevent thrombosis of the artery, two subcu-
taneous injections of heparin (8 IU, Roche in 0.3 ml
saline) were given, one at the beginning and one at the
end of the period of ischemia. In all the groups, silk
suture was removed after 3 h ischemic event to allow rep-
erfusion up to 21 days study protocol. Blood flow was
checked under a microscope at the distal site of ligature
after removing the silk thread. The animals were placed
under heating lamps until they recovered from anesthe-
sia.
Behavioral Study
Hot plate test Thermal nociceptive threshold, as an
index of thermal-hyperalgesia, was assessed by the hot
plate test as described by Andreas and Rainer [20]. Eddy's
hot plate was pre-heated and maintained at temperature
of 52.5 ± 0.5°C. Rats were placed on the hot plate and
nociceptive threshold was assessed with respect to hind
paw licking. Response was recorded in seconds. Cut-off
time of 20 s was maintained.
Plantar test Radiant heat sensitivity of right hind paw
was measured under the radiant heat lamp source as
described by Hargreaves et al., [21]. The intensity of the
radiant heat stimulus was maintained at 25 ± 0.1°C.
Response of paw withdrawal latency was noted in sec-
onds. Cut-off time of 15 s was maintained.
Acetone drop test Thermal (non-noxious cold) non-
nociceptive threshold, as an index of cold allodynia, was
assessed by using acetone drop method as described by
Choi  et al., [22]. The reactivity to non-noxious cold
chemical stimuli was assessed. Rat was placed on the top
of the wire mesh grid, allowing access to the hind paws.
Acetone (100 μl) was sprayed on the plantar surface of the
hind paw of rat and time taken to appear the cold sensi-
tive reaction with respect to either paw licking, shaking
or rubbing the hind paw was recorded within 20 seconds.
Tail heat hyperalgesia test Spinal thermal sensitivity
was assessed by the tail immersion test as described by
Necker and Hellon [23]. Tail heat-hyperalgesia was noted
with the immersion of terminal part of the tail (1 cm) in
water, temperature was maintained at 52.5 ± 0.5°C. Dura-
t i o n  o f  t h e  t a i l  w i t h d r a w a l  r e f l e x  w a s  r e c o r d e d ,  a s  a
response of spinal heat sensation and a cut-off time of 15
s was maintained.
Tail flick test Spinal thermal sensitivity was assessed by
the tail flick test as described by D'Amour and Smith [24].
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gesiometer was maintained at 52 ± 0.5°C. The tail of rat
was placed on analgesiometer at uniform distance from
the nichrome wire. The tail flick response was noted and
cut-off time of 15 s was maintained.
Tail cold allodynia test Spinal thermal sensitivity was
assessed by the tail immersion test as described by
Necker and Hellon [23]. Briefly, the terminal part of the
tail (1 cm) of the rat was immersed in cold non-noxious
temperature (8 ± 0.5°C), until the tail was withdrawn. The
duration of the tail withdrawal reflex was recorded and a
cut-off time of 20 s was used.
Biochemical study
Blood samples were collected by retro-orbital sinus punc-
ture at different day's interval (i.e., day 0, 4, 8, 12, and
16th). Serum samples were prepared for the evaluation of
oxidative stress marker (nitrate and TBARS) changes in
rats. Further, tissue samples were employed to estimate
reduced glutathione, total calcium, MPO and histopatho-
logical evaluation.
Estimation of serum nitrate level The oxidized end
product of NO i.e. nitrate was measured in serum sam-
ples using a procedure based on the Griess reaction [25].
Potassium nitrate (80 mM) was used as a standard for the
determination of nitrate. Serum nitrate levels were
expressed as μmol/L.
Estimation of lipid peroxidation (TBARS) Serum
malondialdahyde (MDA) level, an index of lipid peroxida-
tion, was determined by thiobarbituric acid (TBA) reac-
tion. The principle of the method depends on
measurement of the pink color produced by interaction
of barbituric acid with malondialdahyde. 1,1,3,3-tetra-
ethoxypropane was used as a primary standard. The
determination of MDA level was performed by the
method of Yagi [26]. Serum MDA levels were expressed
as nmol/ml.
Estimation of total protein content Protein concentra-
tion was estimated according to the method of Lowry et
al., [27] using bovine serum albumin as a standard. The
absorbance was determined spectrophotometrically at
750 nm.
Estimation of reduced glutathione Reduced glutathi-
one levels were estimated according to the method of Ell-
man [28]. Equal quantity of tissue homogenate was mixed
with 10% trichloroacetic acid and centrifuged to separate
out protein. To 0.01 ml of this supernatant, 2 ml of phos-
phate buffer (pH 8.4), 0.5 ml of 5,5'-dithio, bis(2-
nitrobenzoic acid) and 0.4 ml of double distilled water
was added. Mixture was vortexed and the absorbance was
taken at 412 nm within 15 min. The concentration of
reduced glutathione was expressed as μmol/g of protein.
Estimation of total calcium Total calcium levels were
estimated in the sciatic nerve as described by Severng-
haus and Ferrebee [29] and Muthuraman et al., [12].
Briefly, the sciatic nerve homogenate was mixed with 1
mL of trichloroacetic acid (4%) in the ice-cold condition
and centrifuged at 1500 × g for 10 min. The clear super-
natant was used for estimating the total calcium levels by
atomic emission spectroscopy at 556 nm.
Estimation of myeloperoxidase activity MPO, an
enzyme liberated due to activation of polymorphonuclear
leukocytes, is used as an indication of tissue neutrophil
accumulation. MPO activity was measured using a proce-
dure similar to that documented by Hillegass et al., [30].
Sciatic nerve tissues were homogenized in 50 mM potas-
sium phosphate buffer (pH 6.0), and centrifuged at 2500
rpm (10 min); pellets were resuspended in 50 mM phos-
phate buffer containing 0.5% hexadecyltrimethylammo-
niumbromide (HETAB). After three freeze and thaw
cycles, with sonication between cycles, the samples were
centrifuged at 2500 rpm for 10 min. Aliquots (0.3 ml)
were added to 2.3 ml of reaction mixture containing 50
mM phosphate buffer, o-dianisidine, and 20 mmol H2O2
solution. The presence of MPO was measured at 460 nm
for 3 minutes. MPO activity was expressed as U per g tis-
sue. One unit of MPO activity was defined as that degrad-
ing 1 μmol peroxide per min at 25°C.
Histopathological study
Assessment of axonal degeneration Samples of sciatic
nerve were stored in the fixative solution (10% formalin)
and cut into 4 μm thickness size. Staining was done by
using hematoxylin and eosin as described by Yukari et al.,
[31]. Nerve sections were analyzed qualitatively under
light microscope (450 ×) for axonal degeneration.
Experimental Design Seven groups were employed in
the present study, each consist of six Wistar rats.
Group I (Normal control group)
Rats were not subjected to any surgical procedure and
were kept for 21 days. Behavioral tests were employed to
assess nociceptive threshold on day 0, 1, 4, 7, 10, 13 and
16st whereas, biochemical analysis was performed for the
estimation of serum nitrate and TBARS on day i.e., day 0,
4, 8, 12, and 16, all animals were sacrificed by cervical dis-
location and sciatic nerve tissues were immediately iso-
lated for the study of biochemical (reduced glutathione,
total calcium and MPO) and histopathological changes.
Group II - Sham control group
Rats were subjected to surgical procedure to expose right
femoral artery without any vascular damage and isch-
emia. Behavioral and biochemical tests were employed on
different days as described in group I.
Group III - Ischemia-reperfusion control group 
[I/R]
Rats were subjected to surgical procedure to expose and
develop 3 h ischemia followed by prolong reperfusion onMuthuraman and Sood Journal of Brachial Plexus and Peripheral Nerve Injury
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Figure 1 Time course of paw thermal hyperalgesia was measured against noxious conduct heat evoked hind paw licking response. Data 
were expressed as mean ± S.E.M., n = 6 rats per group. a = p < 0.05 vs sham control group, b = p < 0.05 vs I/R control group.
 
Figure 2 Time course of peripheral thermal hyperalgesia was measured against noxious radiant heat evoked ipsilateral right hind paw 
withdrawal response. Data were expressed as mean ± S.E.M., n = 6 rats per group. a = p < 0.05 vs sham control group, b = p < 0.05 vs I/R control 
group.
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right femoral artery. Behavioral tests and biochemical
parameters were assessed as described in group I.
Group IV - Vehicle treated group [I/R + Vehicle]
Vehicle (1% CMC p.o.) was administered to all the rats
upto the end of the study protocol. Behavioral tests and
biochemical parameters were assessed as described in
group I.
Group V to VII - FK-506 treated group [I/R + FK-
506 (1, 2 and 3 mg/kg)]
FK-506 (1, 2 and 3 mg/kg, p.o.) doses were administered
in group V to VII respectively upto the end of the study
protocol. Behavioral tests and biochemical parameters
were assessed as described in group I.
Statistical Analysis All the results were expressed as
mean ± standard error of means (S.E.M). Data obtained
from behavioral and serum biochemical tests were statis-
tically analyzed using two-way analysis of variance
(ANOVA). The data of tissue biomarker total calcium
and MPO were analyzed using one way analysis of vari-
a n c e  ( A N O V A ) .  I n  b o t h  c a s e s ,  T u k e y ' s  m u l t i p l e  r a n g e
tests were applied for post-hoc analysis by using Graph
pad prism Version-5.0 software. A probability value of p <
0.05 was considered to be statistically significant.
Results
Behavioral study
Peripheral thermal (conduction, radiant and chemical)
sensitivity was assessed by paw withdrawal threshold and
paw lifting duration, as an index of heat hyperalgesia and
chemical allodynia by using hot plate, radiant heat lamp
and acetone applicator respectively as shown in figure 1,
2 and 3. I/R of femoral artery showed significant decrease
in paw withdrawal threshold and increase in paw lifting
duration at different days with maximum effect shown at
7th day as compared to sham control group. Whereas, tac-
rolimus treated groups V to VII showed increase in paw
withdrawal threshold and decrease in paw lifting dura-
tion but significant results were observed only in the
medium and high dose (2 and 3 mg/kg, p.o.) treated
groups as compared to I/R control group.
Spinal thermal (conduction and radiant) and cold sensi-
tivity were assessed by tail withdrawal latency, as an index
of heat hyperalgesia and cold allodynia by using hot water
(52 ± 0.5°C), analgesiometer and cold water (8 ± 0.5°C)
respectively as shown in figure 4, 5 and 6. I/R of femoral
artery showed significant decrease in tail withdrawal
latency at different days with maximum effect shown at
7th day as compared to sham control group. Whereas, tac-
Figure 3 Time course of paw cold allodynia was measured against non-noxious chemical cold evoked paw withdrawal response. Data were 
expressed as mean ± S.E.M., n = 6 rats per group. a = p < 0.05 vs sham control group, b = p < 0.05 vs I/R control group.
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rolimus treated groups V to VII showed increase in tail
withdrawal latency but significant results were observed
only in the medium and high dose (2 and 3 mg/kg, p.o.)
treated groups as compared to I/R control group.
Biochemical study
I/R control group had shown increase in serum nitrate
and TBARS levels as compared to sham control group at
different day's interval. Further, sciatic nerve tissue sam-
ples also showed significant changes in biochemical
parameters i.e. increased total calcium level and MPO
activity but decreased reduced glutathione level as com-
pared to sham control group. However, tacrolimus
treated groups V to VII showed ameliorative effect on
serum and tissue biomarker changes but significant
results were observed only in the medium and high dose
(2 and 3 mg/kg, p.o.) treated groups as compared to I/R
control group (Table 1 and 2).
Histopathological study
I/R injury of femoral artery resulted in significant histo-
pathological changes which were assessed in cross sec-
tional section of distal part of sciatic nerve. In cross
section, axonal degeneration was shown by decrease in
number of myelinated fibers along with swelling of non-
myelinated and myelinated nerve fibers. But tacrolimus
treatment (2 and 3 mg/kg) resulted in attenuation of I/R
induced axonal degeneration and histopathological alter-
ations (Fig. 7).
Discussion
In the present study, tacrolimus showed significant ame-
lioration of ischemia reperfusion induced behavioral, bio-
chemical and histopathological changes. Literature
revealed that ischemia followed by reperfusion can cause
severe damage in heart, intestine, kidney, stomach, brain
and peripheral nerve [32]. Ischemic insult of vascular and
nervous system in vascular occlusive diseases, necrotiz-
Figure 4 Time course of tail thermal hyperalgesia was measured against noxious warm water immersion evoked tail withdrawal response. 
Data were expressed as mean ± S.E.M., n = 6 rats per group. a = p < 0.05 vs sham control group, b = p < 0.05 vs I/R control group.
 Muthuraman and Sood Journal of Brachial Plexus and Peripheral Nerve Injury
2010, 5:13
Page 7 of 11
ing vasculitides, diabetes mellitus and trauma plays a
major key role in the development of ischemic pain, vas-
culatic neuropathic pain etc [33,14]. Severe ischemic
insult in nerve has resulted in the energy shutdown fol-
lowed by conduction failure and fiber degeneration [19].
The most important hypothesis explains that the neu-
ronal cellular reperfusion induced damage is caused by
enhancement of the free radical generation, lipid peroxi-
dation, calcium overload, alteration in the level of nitrite/
nitrate, pro/anti-inflammatory cytokines and neuronal
apoptotic components, endoneurial edema and augmen-
tation of fiber degeneration [34]. Both ischemic insult
and reperfusion process can alter the structural and func-
tional action of the certain targeted cells. In the present
study the peripheral nerve has been targeted for induc-
tion of vasculatic neuropathy in rats by the process of
femoral artery I/R. The event of femoral artery I/R pro-
cess has been well documented for the induction of the
neuro-inflammation, neuronal excitability and enhance-
ment of pain sensation [35].
The production of reactive oxygen species and reactive
nitrogen species (ROS/RNS) in severe oxidative stress
conditions such as sepsis, trauma, surgery, ischemia,
hypoxia and ischemia-reperfusion lead to the loss of
membrane integrity and structural or functional changes
[36]. Further, generation of free radicals can cause neu-
ronal and endothelial damage through the induction of
lipid peroxidation, protein oxidation and direct damage
to nucleic acids [37]. Nitric oxide (NO) is an important
endogenous vasodilator in the vascular system and plays
a protective role in the cardiovascular and other vital
organ system. In contrast, it has been suggested that the
neuronal blood flow is maintained at low concentration
of NO and the excessive release of NO may be toxic to the
nerve cells [38]. This toxicity may be exacerbated during
ischemia and reperfusion due to generation of O2 leading
Figure 5 Time course of tail thermal hyperalgesia was measured against noxious radiant heat evoked tail withdrawal response. Data were 
expressed as mean ± S.E.M., n = 6 rats per group. a = p < 0.05 vs sham control group, b = p < 0.05 vs I/R control group.
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to formation of the peroxynitrite radicals [39]. In the
present study, the effect of I/R induced behavioral
changes were assessed by the hot plate, plantar, acetone
drop, tail (heat and cold water) immersion and tail flick
tests. Further, neuro-vascular changes were evaluated by
direct measurement of the level of nitrate and TBARS in
serum and tissue reduced glutathione, total calcium and
MPO activity. Results obtained had confirmed I/R injury
induced vasculatic neuropathy in rats. However, tacroli-
mus treatment had resulted in the reduction of such neu-
ropathic pain along with ameliorative effect on
biochemical parameters and such I/R induced vasculatic
neuropathy clinically resemble to diabetic, rheumatoid
vasculatitis, vascular inflammatory and demyelinating
related neuropathy [40].
Ischemia reperfusion induced vasculitic neuropathy
has shown compelling evidence for the role of myeloper-
oxidase due to mast cell activation. The pathogenesis of
vasculitis is complex and is the result of various autoim-
mune reactions, both humoral and cell mediated. There
are multiple triggering events or antigens leading to vari-
ous immunological and histological responses [41].
Moreover, free radicals are also found to be involved in
chronic constriction injury, tibial sural transection, axo-
tomy, traumatic injury and peripheral ischemia reperfu-
sion induced neuropathic pain [6,12,13]. Peripheral
ischemia is recognized as a secondary phenomenon in
patients with peripheral arterial disease, vasculatic neu-
ropathy etc. Obstruction of the peripheral arteries of the
legs develop peripheral nerve dysfunctions including
peripheral ischemic pain in the lower limbs which may be
due to the free radicals generation, immune cell activa-
tion, calpain activation etc [42].
It is well known that tacrolimus (FK-506) inhibit the
induction of iNOS by suppressing the activation of
nuclear factor kappa-B (NF-κB) [43]. Recently, it has also
been reported that the anti-oxidative, anti-inflammatory
and calcium modulatory actions of tacrolimus prevented
Figure 6 Time course of tail thermal allodynia was measured against non-noxious cold water immesion evoked tail withdrawal response. 
Data were expressed as mean ± S.E.M., n = 6 rats per group. a = p < 0.05 vs sham control group, b = p < 0.05 vs I/R control group.
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gastric mucosal lesions [18]. Results revealed that tacroli-
mus reduce serum nitrate and TBARS levels along with
reduction in the tissue total calcium and MPO activity
but it showed increase in tissue reduced gluthathion lev-
els. Therefore, from the above discussion it may be con-
cluded that these ameliorative effects on various
biomarkers may be due to its effect on decrease in free
radical accumulation and inflammatory markers as well
as its calcium modulatory actions [18,44].
Histopathological evaluation had also revealed I/R
induced axonal degeneration. In fact in I/R induced
axonal degeneration, calcium influx has been considered
as one of the early events following axon injury that sig-
nals the resealing of the severed end by a vesicle mediated
process. Calcium induced activation of calpains has been
reported in the axonal degeneration [12,13]. Calcium
induced activation of calpain is also associated with gen-
eration of reactive oxygen species from mitochondria
[45]. Therefore, tacrolimus prevented the axonal degen-
eration may be due to its calcenurin inhibitor activity.
Conclusion
Hence, it may be concluded that tacrolimus may act as
potential agent for the amelioration of ischemia reperfu-
sion induced neuropathic pain (complex regional pain
Table 1: Effect of tacrolimus on I/R induced changes in serum nitrate and MDA level
Nitrate level 
(μmol/l)
Groups 0 day 4th day 8th day 12th day 16th day
Normal 19.24 ± 0.31 19.91 ± 0.28 19.58 ± 0.42 19. 73 ± 0.34 19.92 ± 0.49
Sham 20. 79 ± 0.39 19.57 ± 0.36 19.87 ± 0.47 19.62 ± 0.32 19.35 ± 0.27
I/R 20.16 ± 0.26 31.43 ± 1.12a 36.27 ± 1.08a 31.27 ± 0.79a 29.82 ± 0. 74a
Vehicle 20.36 ± 0.39 31.26 ± 1.13a 38.16 ± 1.09a 32.53 ± 0.83a 28.93 ± 0.59a
Tacrolimus (1) 20.97 ± 0.28 36.67 ± 1.38a 42.94 ± 1.46a 37.39 ± 0.83a 34.69 ± 1.25a
Tacrolimus (2) 20.62 ± 0.64 43.78 ± 0.64b 49.38 ± 0.46b 44.67 ± 0.46b 41.67 ± 0.32b
Tacrolimus (3) 20.09 ± 0.42 49.59 ± 0.54b 57.35 ± 0.36b 54.56 ± 0.78b 51. 74 ± 0.34b
MDA level 
(nmol/l)
Normal 0.81 ± 0.32 0.83 ± 0.46 0. 79 ± 0.31 0.82 ± 0.36 0.83 ± 0.43
Sham 0.82 ± 0.46 0.81 ± 0.32 0.83 ± 0.31 0.81 ± 0.34 0.85 ± 0.39
I/R 0.74 ± 0.39 18.94 ± 1.74a 24.54 ± 1.56a 18.31 ± 1.58a 16.42 ± 2.23a
Vehicle 0.86 ± 0.23 18.61 ± 1.34a 25.59 ± 1.61a 17.39 ± 1.57a 17.14 ± 2.01a
Tacrolimus (1) 0.82 ± 0.38 26.43 ± 1.58a 33.43 ± 1.67a 28.81 ± 1.58a 26. 74 ± 1.32a
Tacrolimus (2) 0.84 ± 0.36 40.36 ± 1.34b 44.61 ± 1.25b 37.67 ± 1.46b 34.38 ± 1.52b
Tacrolimus (3) 0.81 ± 0.29 49.71 ± 1.45b 56.36 ± 1.54b 49.69 ± 1.39b 46.41 ± 1.23b
Data were expressed as mean ± S.E.M. for each group. a = P < 0.05 vs sham control group, b = P < 0.05 vs ischemia control group.
Table 2: Effect of tacrolimus on I/R induced changes in tissue biomarker level
Groups Reduced Glutathione (μg/
mg of protein)
MPO Activity
(U/min/mg of protein)
Total Calcium
(ppm/mg of protein)
Normal 72.64 ± 2.91 11.32 ± 1.56 3.49 ± 1.04
Sham 71.31 ± 2.47 12.64 ± 1.37 3.59 ± 0.83
I/R 39.25 ± 1.67a 134.01 ± 3.91a 34.61 ± 1.93a
Vehicle 40.54 ± 1.92a 138.43 ± 3.51a 35.19 ± 1.64a
Tacrolimus (1) 46.47 ± 2.65a 126.32 ± 1.47a 31.69 ± 0.57a
Tacrolimus (2) 63.35 ± 1.69b 62.79 ± 2.63b 14.41 ± 2.61b
Tacrolimus (3) 68.41 ± 1.83b 41.84 ± 3.92b 9.16 ± 1.92b
Data were expressed as mean ± S.E.M. for each group.
a = P < 0.05 vs sham control group,
b = P < 0.05 vs ischemia control group.Muthuraman and Sood Journal of Brachial Plexus and Peripheral Nerve Injury
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syndrome) due to its antioxidant, calpain inactivation and
immunosuppressive actions.
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